While efficacy matters, the tolerability and adverse effect profile often determines whether a treatment is suitable for long-term use
This combination is highly prized for its targeted, pulsatile stimulation of endogenous Growth Hormone (GH) release, making it a crucial subject for studies targeting tissue repair, body composition, and overall recovery
Single-target drugs often produce inconsistent results because biological systems are interconnected
While there are several published clinical trials on TB-500, the peptide is not approved by the FDA for human use but is generally available for research purposes
The STEP 1 trial, published in the New England Journal of Medicine, demonstrated 14.9 percent mean body weight reduction with the 2.4mg weekly dose over 68 weeks, compared to just 2.4 percent with placebo